Change in TB diagnostic profile after introduction of GeneXpert MTB/RIF assay in National TB Program of Armenia, 2013-2017
Introduction: In 2013, the National Tuberculosis (TB) Program of Armenia introduced GeneXpert MTB/RIF (Xpert) assay to address World Health Organization (WHO) target of 80% (2020) of notified new and relapse TB cases to be tested with WHO recommended rapid diagnostic methods. This study aimed to as...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Journal of Infection in Developing Countries
2019-05-01
|
| Series: | Journal of Infection in Developing Countries |
| Subjects: | |
| Online Access: | https://jidc.org/index.php/journal/article/view/10920 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849313609948069888 |
|---|---|
| author | Eduard Kabasakalyan Karapet Davtyan Viktorya Cholakyans Alvard Mirzoyan Karine Kentenyants Diana Petrosyan Armen Hayrapetyan Himanshu A Gupte |
| author_facet | Eduard Kabasakalyan Karapet Davtyan Viktorya Cholakyans Alvard Mirzoyan Karine Kentenyants Diana Petrosyan Armen Hayrapetyan Himanshu A Gupte |
| author_sort | Eduard Kabasakalyan |
| collection | DOAJ |
| description |
Introduction: In 2013, the National Tuberculosis (TB) Program of Armenia introduced GeneXpert MTB/RIF (Xpert) assay to address World Health Organization (WHO) target of 80% (2020) of notified new and relapse TB cases to be tested with WHO recommended rapid diagnostic methods. This study aimed to assess the change in laboratory diagnostic profile of Mycobacterium tuberculosis after introduction of the Xpert assay from 2013 to 2017.
Methodology: Retrospective cohort analysis of all presumptive TB patients’ records retrieved from the National Reference Laboratory database was performed.
Results: This study showed increased trend of Xpert coverage for suspected TB cases from 25% in 2013 to 86% in 2017 which is in line with WHO TB global strategy’s target of 80% in 2020. In 4.7% cases, Xpert tested positive while microscopy showed negative results. There was also an improved detection of Rifampicin resistance with increased concordance from 99.1% to 99.4% and decreased discordance from 6.7% to 1.4% between culture and Xpert results.
Conclusion: Armenia has achieved the 2020 target; in terms of utilizing the GeneXpert it is on track to achieve the End TB strategy target of 100% by 2025. The next step of this research will be assessment of the impact of GeneXpert and other TB tests utilization on the treatment outcomes in Armenia.
|
| format | Article |
| id | doaj-art-e98a490abde8403cb60dd98f6d6f8593 |
| institution | Kabale University |
| issn | 1972-2680 |
| language | English |
| publishDate | 2019-05-01 |
| publisher | The Journal of Infection in Developing Countries |
| record_format | Article |
| series | Journal of Infection in Developing Countries |
| spelling | doaj-art-e98a490abde8403cb60dd98f6d6f85932025-08-20T03:52:42ZengThe Journal of Infection in Developing CountriesJournal of Infection in Developing Countries1972-26802019-05-011305.110.3855/jidc.10920Change in TB diagnostic profile after introduction of GeneXpert MTB/RIF assay in National TB Program of Armenia, 2013-2017Eduard Kabasakalyan0Karapet Davtyan1Viktorya Cholakyans2Alvard Mirzoyan3Karine Kentenyants4Diana Petrosyan5Armen Hayrapetyan6Himanshu A Gupte7National Tuberculosis Control Center, SNPO, MoH, ArmeniaFMD K and L Europe Contract Research Organization, Yerevan, ArmeniaNational Tuberculosis Control Center, SNPO, MoH, ArmeniaNational Tuberculosis Control Center, SNPO, MoH, ArmeniaFMD K and L Europe Contract Research Organization, Yerevan, ArmeniaUC Davis Health, Alzheimer ’s disease Center, Walnut Creek, California, United StatesNational Tuberculosis Control Center, SNPO, MoH, ArmeniaNarotam Sekhsaria Foundation, Mumbai, India Introduction: In 2013, the National Tuberculosis (TB) Program of Armenia introduced GeneXpert MTB/RIF (Xpert) assay to address World Health Organization (WHO) target of 80% (2020) of notified new and relapse TB cases to be tested with WHO recommended rapid diagnostic methods. This study aimed to assess the change in laboratory diagnostic profile of Mycobacterium tuberculosis after introduction of the Xpert assay from 2013 to 2017. Methodology: Retrospective cohort analysis of all presumptive TB patients’ records retrieved from the National Reference Laboratory database was performed. Results: This study showed increased trend of Xpert coverage for suspected TB cases from 25% in 2013 to 86% in 2017 which is in line with WHO TB global strategy’s target of 80% in 2020. In 4.7% cases, Xpert tested positive while microscopy showed negative results. There was also an improved detection of Rifampicin resistance with increased concordance from 99.1% to 99.4% and decreased discordance from 6.7% to 1.4% between culture and Xpert results. Conclusion: Armenia has achieved the 2020 target; in terms of utilizing the GeneXpert it is on track to achieve the End TB strategy target of 100% by 2025. The next step of this research will be assessment of the impact of GeneXpert and other TB tests utilization on the treatment outcomes in Armenia. https://jidc.org/index.php/journal/article/view/10920TuberculosisGeneXpert MTB/RIFDiagnosisNRLLaboratory |
| spellingShingle | Eduard Kabasakalyan Karapet Davtyan Viktorya Cholakyans Alvard Mirzoyan Karine Kentenyants Diana Petrosyan Armen Hayrapetyan Himanshu A Gupte Change in TB diagnostic profile after introduction of GeneXpert MTB/RIF assay in National TB Program of Armenia, 2013-2017 Journal of Infection in Developing Countries Tuberculosis GeneXpert MTB/RIF Diagnosis NRL Laboratory |
| title | Change in TB diagnostic profile after introduction of GeneXpert MTB/RIF assay in National TB Program of Armenia, 2013-2017 |
| title_full | Change in TB diagnostic profile after introduction of GeneXpert MTB/RIF assay in National TB Program of Armenia, 2013-2017 |
| title_fullStr | Change in TB diagnostic profile after introduction of GeneXpert MTB/RIF assay in National TB Program of Armenia, 2013-2017 |
| title_full_unstemmed | Change in TB diagnostic profile after introduction of GeneXpert MTB/RIF assay in National TB Program of Armenia, 2013-2017 |
| title_short | Change in TB diagnostic profile after introduction of GeneXpert MTB/RIF assay in National TB Program of Armenia, 2013-2017 |
| title_sort | change in tb diagnostic profile after introduction of genexpert mtb rif assay in national tb program of armenia 2013 2017 |
| topic | Tuberculosis GeneXpert MTB/RIF Diagnosis NRL Laboratory |
| url | https://jidc.org/index.php/journal/article/view/10920 |
| work_keys_str_mv | AT eduardkabasakalyan changeintbdiagnosticprofileafterintroductionofgenexpertmtbrifassayinnationaltbprogramofarmenia20132017 AT karapetdavtyan changeintbdiagnosticprofileafterintroductionofgenexpertmtbrifassayinnationaltbprogramofarmenia20132017 AT viktoryacholakyans changeintbdiagnosticprofileafterintroductionofgenexpertmtbrifassayinnationaltbprogramofarmenia20132017 AT alvardmirzoyan changeintbdiagnosticprofileafterintroductionofgenexpertmtbrifassayinnationaltbprogramofarmenia20132017 AT karinekentenyants changeintbdiagnosticprofileafterintroductionofgenexpertmtbrifassayinnationaltbprogramofarmenia20132017 AT dianapetrosyan changeintbdiagnosticprofileafterintroductionofgenexpertmtbrifassayinnationaltbprogramofarmenia20132017 AT armenhayrapetyan changeintbdiagnosticprofileafterintroductionofgenexpertmtbrifassayinnationaltbprogramofarmenia20132017 AT himanshuagupte changeintbdiagnosticprofileafterintroductionofgenexpertmtbrifassayinnationaltbprogramofarmenia20132017 |